Dragon Pharmaceuticals Inc. is pleased to announce that it has appointed Ms. Rita Jervis as VP Corporate Development. Ms. Jervis will be responsible for leading the company’s strategic planning, business development, and investor relations initiatives.
Ms. Jervis brings to her position 14 years of planning and operations experience in the biotechnology sector. In her position as President of Jervis Associates, a management consulting firm established in 1991 to provide interim executive and consulting services to emerging health sector companies, Ms. Jervis has held numerous executive and managing director positions in R&D, contract research, and venture capital firms. In addition, Ms. Jervis recently served as Executive Director of the B.C. Biotechnology Alliance and, prior to establishing Jervis Associates, held project and marketing management positions with QLT Inc. (Nasdaq: QLTI, TSE: QLT)
Dragon Pharmaceuticals also announced today that it has received approval from Standard & Poor’s to trade in 35 U.S. states under the Blue Sky rules and regulations. Dragon’s company listing was published in the January 2, 2001 edition of the Standard & Poor’s Corporation Records, a recognized securities manual widely relied upon by investment officers, pension fund managers, registered representatives, and other financial service professionals to facilitate secondary market trading.
About Dragon Pharmaceuticals Inc.
Dragon Pharmaceuticals is an international biopharmaceutical corporation engaged in the discovery, development and marketing of therapies for infectious diseases, cancer, and cardiovascular diseases. Using proprietary protein expression technology, Dragon has become one of the world’s lowest cost producers of EPO (Erythropoietin), and is currently in the process of applying its technology to six additional generic drugs. Dragon intends to become a leading biotechnology company by delivering generic drugs at affordable prices as well as by developing and commercializing proprietary drugs with worldwide patent potential.
Legal Dragon Pharma
25 total views, 1 today